Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity undergoing treatment with semaglutide.Topline results from the Phase ...

Veru's enobosarm is designed to be used in combination with GLP-1 agonist-based obesity drugs – such as Novo Nordisk's blockbuster Wegovy (semaglutide) – to reduce the loss of lean muscle mass ...

Veru's obesity candidate achieved the objective of preserving muscle in people taking weight-loss drug Wegovy, but its share price still fell sharply. Sales & Marketing Sponsored ...